Our Pipeline

Our diversified and growing pipeline of highly targeted T cell engagers addresses solid tumors and autoimmune diseases – two areas of significant unmet medical need.

Based on more than 20 years of experience in cutting-edge antibody fragment design, engineering and production, CDR-Life’s integrated end-to-end antibody-based platform drives innovation in both oncology and autoimmune disease. In oncology, we develop novel tumor-targeted T cell engagers (TCEs), addressing challenging targets on hard-to-treat solid tumors that offer enhanced cancer selectivity. For autoimmune conditions, we target specific immune cell populations with the goal to reset the immune system to a healthy state.

With this pipeline, we aim to increase therapeutic efficacy while minimizing side effects across both disease areas. Our lead program, CDR404 is in clinical testing.

CDR-Life’s unique M-gager® platform has the capability to target a broad spectrum of disease-specific antigens. In oncology, this includes challenging surface antigens and intracellular antigens displayed on the major histocompatibility complex (MHC). For autoimmune conditions, we precisely target disease-driving immune cell populations. Our modular format with unparalleled antigen binding specificity enables selective targeting of diseased cells while sparing healthy tissues. By combining precise targeting with a modular and flexible format, CDR-Life is developing truly selective therapeutics that can either activate or regulate immune responses based on disease context.